

**Anti-IL-23a Reference Antibody (risankizumab)  
Recombinant Antibody  
Catalog # APR10031****Specification**

---

**Anti-IL-23a Reference Antibody (risankizumab) - Product Information**

Application	FC, Kinetics, Animal Model
Primary Accession	<a href="#">Q9NPF7</a>
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145.92 KDa

**Anti-IL-23a Reference Antibody (risankizumab) - Additional Information****Target/Specificity**  
IL-23a**Endotoxin**  
< 0.001EU/ µg,determined by LAL method.**Conjugation**  
Unconjugated**Expression system**  
CHO Cell**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Anti-IL-23a Reference Antibody (risankizumab) - Protein Information****Name** IL23A**Synonyms** SGRF**Function**  
Associates with IL12B to form the pro-inflammatory cytokine IL-23 that plays different roles in innate and adaptive immunity (PubMed:<a href="http://www.uniprot.org/citations/11114383" target="\_blank">11114383</a>). Released by antigen-presenting cells such as dendritic cells or macrophages, binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R to activate JAK2 and TYK2 which then phosphorylate the receptor to form a docking site leading to the phosphorylation of STAT3 and STAT4 (PubMed:<a href="http://www.uniprot.org/citations/29287995" target="\_blank">29287995</a>, PubMed:<a href="http://www.uniprot.org/citations/32474165" target="\_blank">32474165</a>, PubMed:<a href="http://www.uniprot.org/citations/33606986" target="\_blank">33606986</a>). This process leads to activation of several pathways including p38 MAPK or NF-kappa-B and promotes the

production of pro- inflammatory cytokines such as interleukin-17A/IL17A (PubMed:<a href="http://www.uniprot.org/citations/12023369" target="\_blank">12023369</a>). In turn, participates in the early and effective intracellular bacterial clearance (PubMed:<a href="http://www.uniprot.org/citations/32474165" target="\_blank">32474165</a>). Promotes the expansion and survival of T-helper 17 cells, a CD4-positive helper T-cell subset that produces IL-17, as well as other IL-17-producing cells (PubMed:<a href="http://www.uniprot.org/citations/17676044" target="\_blank">17676044</a>).

#### Cellular Location

Secreted. Note=Secreted upon association with IL12B

#### Tissue Location


Secreted by activated dendritic and phagocytic cells and keratinocytes. Also expressed by dermal Langerhans cells (at protein level).

### Anti-IL-23a Reference Antibody (risankizumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


### Anti-IL-23a Reference Antibody (risankizumab) - Images



Anti-IL-23a Reference Antibody (risankizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-IL-23a Reference Antibody (risankizumab) is more than 100% ,determined by SEC-HPLC.



Immobilized human IL 23P40 His at 2 µg/mL can bind Anti-IL-23a Reference Antibody (risankizumab)  $EC_{50}=0.04262$  µg/mL.